APA (7th ed.) Citation

T, v. M., J, K., KW, S., C, T., MC, M., E, F., . . . MS, T. (2024). Impact of debulking therapy on the clinical outcomes of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphoma. American journal of cancer research, 14(6), 2905. https://doi.org/10.62347/LLXR8002

Chicago Style (17th ed.) Citation

T, van Meerten, et al. "Impact of Debulking Therapy on the Clinical Outcomes of Axicabtagene Ciloleucel in the Treatment of Relapsed or Refractory Large B-cell Lymphoma." American Journal of Cancer Research 14, no. 6 (2024): 2905. https://doi.org/10.62347/LLXR8002.

MLA (9th ed.) Citation

T, van Meerten, et al. "Impact of Debulking Therapy on the Clinical Outcomes of Axicabtagene Ciloleucel in the Treatment of Relapsed or Refractory Large B-cell Lymphoma." American Journal of Cancer Research, vol. 14, no. 6, 2024, p. 2905, https://doi.org/10.62347/LLXR8002.